Research News and Research

RSS

Aspirin surgery on neck arteries can prevent complications

Popping an aspirin the night before you are due to have surgery on neck arteries could help prevent a dangerous complication, a team of researchers at the University of Leicester has discovered.

30 Mar 2004

Scientists find parallels between human speech and bird song which gives clues to human speech disorders.

The research by a team led by Stephanie White, UCLA assistant professor of physiological science, supports the theory that two genes shared by humans and songbirds, FoxP1 and FoxP2, may play a critical role in human speech, and speech disorders. The study is published March 31 in the Journal of Neuroscience.

30 Mar 2004

Zebrafish show effects of ionizing and UV radiation differ during embryo development

Adam Dicker, M.D., Ph.D., associate professor of radiation oncology at Jefferson Medical College of Thomas Jefferson University and Jefferson’s Kimmel Cancer Center in Philadelphia, Mary Frances McAleer, M.D., Ph.D., a resident in the Department of Radiation Oncology at Jefferson Medical College and their co-workers compared the effects on zebrafish embryos of two types of radiation – ionizing radiation, which is the kind given to patients for cancer treatment, and ultraviolet (UV) radiation, which comes naturally from the sun.

30 Mar 2004

Discovery of novel gene profile that may identify colon stem cells

Researchers at Jefferson Medical College have uncovered a novel pattern of gene expression in the stem cell-rich bottom of tiny “crypts” in the tissue lining the colon. By identifying these patterns, the scientists hope to be able to identify mechanisms through which stem cells contribute to the development of colon cancer.

30 Mar 2004

£1.6m for research into a possible cure for muscular dystrophy

A consortium which includes Oxford researchers has won £1.6m in government funding for ground-breaking research into a possible cure for muscular dystrophy.

30 Mar 2004

First Canadian therapeutic HIV vaccine trial

Clinicians from the McGill University Health Centre and the Centre hospitalier de l'Université de Montréal (CHUM) are participating in the first Canadian therapeutic HIV vaccine trial. Funded by a number of public and private institutions, including the Canadian Network for Vaccines and Immunotherapeutics (CANVAC) and the Canadian Institutes of Health Research, this project will begin in April.

30 Mar 2004

Newly diagnosed non-Hodgkin’s lymphoma linked to monkey virus DNA

Examination of tumors in patients with newly diagnosed non-Hodgkin’s lymphoma found that half of them show evidence of a monkey virus DNA that may have originated from contaminated polio vaccines.

30 Mar 2004

Human Genome Sciences can begin cardiovascular disease research

Human Genome Sciences, Inc.announced today that it has received a clinical development milestone payment from its partner, GlaxoSmithKline, related to the initiation of Phase 1 clinical trials of 677116 for the treatment of cardiovascular disease. 677116 is a small-molecule inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2), an enzyme associated with the formation of atherosclerotic plaques.

30 Mar 2004

Extraction of RNA from Archived Formalin-Fixed, Paraffin-Embedded Tissue

For the first time, Fox Chase Cancer Center researchers have demonstrated the ability to extract RNA from formalin-fixed, paraffin-embedded tissue samples archived for up to five years. What's more, the technology used retrieves high-quality samples, allowing researchers to identify cancer-related genetic changes. Accepted as a "late-breaking" abstract, the research was presented today at the 95th Annual Meeting of the American Association for Cancer Research by Renata Coudry, M.D., a research pathologist at Fox Chase Cancer Center.

30 Mar 2004

Novel uses for bacterial cellulose, artificial blood vessels, bioengineered wound dressing

New and unique products created from bacterial cellulose — from electronic paper to treatment for wounds — will highlight a one-day symposium at the 227th national meeting of the American Chemical Society, the world's largest scientific society.

30 Mar 2004

Biocompatible adhesives for use with vascular tissue that will speed the process of mending tissue

Surgeons battle time and the body's defenses as they stitch together veins and arteries, whether after an injury or in the course of such treatments as transplants or bypasses. Loss of blood before a site is closed and too much clotting soon after challenge medical care.

30 Mar 2004

New storage method amplifies cells available for science

Like many other kinds of cells used in biomedical research, human embryonic stem cells are stored and transported in a cryopreserved state, frozen to -320 degrees Fahrenheit, the temperature of their liquid nitrogen storage bath. But when scientists thaw the cells for use in the lab, less than 1 percent awake from their frigid slumber and assume their undifferentiated state. This 'blank slate' form is characteristic of stem cells and essential for the basic science required before the promising cells are ready for the clinic.

30 Mar 2004

Researchers find new purpose for existing drugs to suppress colon cancer metastasis, secure post-radiation brain function, and trick tumors

Drugs approved for treatment of specific maladies sometimes show unexpected benefits. Researchers at the 95th annual meeting of the American Association for Cancer Research demonstrated highlighted how some drugs may one day offer previously unforeseen benefits for patients.

30 Mar 2004

Emerging technologies in tissue engineering and regenerative medicine analysis

Pathbreaking developments in tissue engineering and regenerative therapies are facilitating the design and growth of new organs in labs using biopolymer scaffolds and matrices. Analysis of potential markets for tissue engineering reveals that basic problems such as vascularity must be solved before such implants can gain acceptance as standard treatment methods.

30 Mar 2004

Alzheimer’s Association asks for $40 million in additional funding

The Alzheimer’s Association today called on the House of Representatives to provide $40 million in additional funding this year to the National Institutes of Health NIH) to support large-scale clinical trials for treatments that would slow or delay the progression of Alzheimer’s disease.

30 Mar 2004

Genencor Sells Its Therapeutic Vaccine Program to Innogenetics

Genencor International, Inc. today announced that it has agreed to sell its therapeutic vaccine program to Belgian biotechnology company Innogenetics N.V. Innogenetics will develop and commercialize current product candidates in Genencor’s vaccine product portfolio as well as future products based on intellectual property and technology held by Genencor.

30 Mar 2004

Trial of new drug that may halt progression of Type I Diabetes

The results of a long-term clinical trial on a new drug designed to inhibit the progression of type I diabetes was announced at the International Diabetes Society meeting in Cambridge, England, March 29. The findings of the 18-month long clinical trial confirm the drug's efficacy in improving a diabetic's ability to produce insulin.

30 Mar 2004

Antarctic fish may aid cardiac research

A species of fish that lives in Antarctic waters may hold clues to climate change and lead to advances in heart medicine. Researchers from the University of Birmingham and the British Antarctic Survey (BAS) are investigating the behaviour and physiology of the little-known 'Antarctic Cod' that has survived in Antarctica's extreme environment for around 30 million years.

30 Mar 2004

75% of young Britains still ignoring skin cancer warnings

Almost three quarters of Britain's young men and women are boosting their risk of potentially fatal skin cancer in their search for a suntan. A specially commissioned survey for Cancer Research UK today reveals that 70 per cent of 16 to 24 year olds still want a tan on holiday despite warnings of over exposure to the sun.

30 Mar 2004

World’s largest biotechnology company acquires Tularik

Amgen Inc., the world’s largest biotechnology company, and Tularik Inc., a pioneer in drug discovery related to cell signaling and the control of gene expression, today jointly announced that they have signed a definitive merger agreement whereby Tularik will become a wholly-owned subsidiary of Amgen in a stock for stock transaction.

30 Mar 2004